Ann Mongan, director of translational research at BMS, outlines how biomarkers hold pivotal roles in clinical trials.
Historically, pregnant women have been excluded from clinical trials due to safety concerns, but the WHO is pushing for change.
CatalYm has commenced dosing the first subject in its Phase II/III VINCIT trial, assessing the safety and efficacy of its lead anti-GDF-15 antibody, visugromab, in cancer-associated cachexia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results